Former U.S. President Joe Biden has commenced a five-week course of radiation therapy and hormone treatment for aggressive prostate cancer, initially diagnosed in May, which had metastasized to his bones. This new phase of care, announced by his spokesperson, follows earlier hormone medication and Mohs surgery for skin cancer.
Former U.S. President Joe Biden has commenced a five-week course of radiation therapy and hormone treatment for aggressive prostate cancer, initially diagnosed in May. This new phase of care follows an earlier diagnosis which indicated the cancer had metastasized to his bones, as confirmed by his spokesperson and first reported by NBC. He had previously been taking hormone medication and underwent Mohs surgery for skin cancer in September. Despite the high profile of the individual involved, the financial market impact of this health update is assessed as neutral. General sentiment and market impact scores are both 0.0, indicating no discernible effect on broader market conditions or specific sectors. The mention of Thomson Reuters (TRI) is solely due to its reporting contribution and does not imply any direct business or financial implications for the company itself from this news event.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
